Redeye makes minor revisions based on the Q1 report. Ortoma showed higher net sales than we expected, adjusting for milestones not included in the quarter. The progress is evident in our view, and with the approvals during the quarter and the now-announced milestone coming in Q2, the outlook is very promising. We maintain our fair value range while increasing our Base case to SEK18.7 (18.0) per share.